297 related articles for article (PubMed ID: 15301561)
21. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease.
Beigel F; Jürgens M; Filik L; Bader L; Lück C; Göke B; Ochsenkühn T; Brand S; Seiderer J
Inflamm Bowel Dis; 2009 Aug; 15(8):1240-4. PubMed ID: 19217020
[TBL] [Abstract][Full Text] [Related]
22. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
23. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
Keane J; Gershon S; Wise RP; Mirabile-Levens E; Kasznica J; Schwieterman WD; Siegel JN; Braun MM
N Engl J Med; 2001 Oct; 345(15):1098-104. PubMed ID: 11596589
[TBL] [Abstract][Full Text] [Related]
24. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
Siddiqui MA; Scott LJ
Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377
[TBL] [Abstract][Full Text] [Related]
25. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
26. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
27. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
28. Infliximab (Remicade), a new biological treatment for Crohn's disease.
D'Haens GR
Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
[TBL] [Abstract][Full Text] [Related]
29. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
Hyams JS; Markowitz J; Wyllie R
J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
[TBL] [Abstract][Full Text] [Related]
30. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
31. Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease.
Regueiro M; El-Hachem S; Kip KE; Schraut W; Baidoo L; Watson A; Swoger J; Schwartz M; Barrie A; Pesci M; Binion D
Dig Dis Sci; 2011 Dec; 56(12):3610-5. PubMed ID: 21681507
[TBL] [Abstract][Full Text] [Related]
32. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
33. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
Lamireau T; Cézard JP; Dabadie A; Goulet O; Lachaux A; Turck D; Maurage C; Morali A; Sokal E; Belli D; Stoller J; Cadranel S; Ginies JL; Viola S; Huet F; Languepin J; Lenaerts C; Bury F; Sarles J;
Inflamm Bowel Dis; 2004 Nov; 10(6):745-50. PubMed ID: 15626892
[TBL] [Abstract][Full Text] [Related]
35. What next after infliximab?
Baidoo L; Lichtenstein GR
Am J Gastroenterol; 2005 Jan; 100(1):80-3. PubMed ID: 15654785
[TBL] [Abstract][Full Text] [Related]
36. Advances in medical therapy for Crohn's disease.
D'Haens G; Hlavaty T
Curr Gastroenterol Rep; 2004 Dec; 6(6):496-505. PubMed ID: 15527680
[TBL] [Abstract][Full Text] [Related]
37. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
38. Review article: safety of infliximab in clinical trials.
Hanauer SB
Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():16-22; discussion 38. PubMed ID: 10597335
[TBL] [Abstract][Full Text] [Related]
39. Anti-TNF therapy in Crohn's disease.
Ghosh S
Novartis Found Symp; 2004; 263():193-205; discussion 205-18. PubMed ID: 15669643
[TBL] [Abstract][Full Text] [Related]
40. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
